Obsidian Therapeutics, Inc. OBX
Obsidian Therapeutics, Inc. (Nasdaq: OBX) is an oncology drug developer. Its lead program, amsoki-cel (OBX-115), is in Phase 2 for Advanced melanoma (second-line, post-ICI); also NSCLC. Its next catalyst on record is amsoki-cel (OBX-115): Updated melanoma RP2D data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: amsoki-cel (OBX-115) — Updated melanoma RP2D data (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| amsoki-cel (OBX-115) - Agni-01 registration-enabling cohort | second-line advanced melanoma | cell therapy | Phase 2 |
| amsoki-cel (OBX-115) first-line cohort | first-line advanced melanoma | cell therapy | Phase 2 |
| amsoki-cel (OBX-115) | non-small cell lung cancer | cell therapy | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
- Faeth Therapeutics, Inc. FTH
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.